S&P 500 769.46 ▼0.21% Nasdaq 100 716.48 ▼0.64% Dow 535.00 ▼0.04% AAPL 319.67 ▲1.62% MSFT 514.67 ▲1.90% NVDA 218.55 ▼4.14%
Stocks

Microsoft Leads the Chip-and-Cloud Tape as Semis Stay in Favor

Big tech split on the tape Monday: Microsoft and Nvidia rallied, Apple sold off, and AMD barely budged. With JPMorgan flagging a preference for semis over hyperscalers, the leadership question is back in play.

a close up of a printed circuit board

TL;DR

  • Microsoft led our watchlist with a 4.86% pop to $487.30, while Nvidia added 2.78% to $206.34.
  • Apple bucked the trend, falling 1.54% to $304.15; AMD was effectively flat at +0.35% ($477.81).
  • JPMorgan strategists reportedly prefer semiconductor stocks to hyperscalers and see non-U.S. shares performing well later in the cycle.

The takeaway from Monday’s tape is dispersion, not direction. Among the megacap names we track, Microsoft was the clear standout, surging 4.86% to $487.30, with Nvidia close behind at +2.78% to $206.34. But the rally wasn’t universal: Apple slipped 1.54% to $304.15, and AMD stalled out at +0.35% to $477.81. In other words, this was a stock-picker’s session inside big tech, not a wholesale bid on the group.

The scoreboard

SymbolPriceChange %
MSFT$487.30+4.86%
NVDA$206.34+2.78%
AMD$477.81+0.35%
AAPL$304.15-1.54%

The spread from top to bottom is telling. Microsoft’s 4.86% gain and Apple’s 1.54% decline mark a roughly 6.4-percentage-point gap between the best and worst performers on the list. That kind of divergence is what you’d expect when investors are actively reallocating within tech rather than treating it as a single trade.

Semis over hyperscalers?

The move lines up with a shifting narrative on Wall Street. According to JPMorgan strategists, tech stocks are ‘likely to take a back seat’ for the rest of 2026, with the bank favoring semiconductor names over hyperscalers and expecting non-U.S. shares to perform well in the second half of the cycle. Nvidia’s 2.78% advance fits the semiconductor-preference thesis, though AMD’s near-flat 0.35% shows the enthusiasm isn’t spread evenly across the chip complex.

Why this matters

If strategists are right that semis will lead while broad tech cools, leadership could narrow to specific chipmakers rather than the entire megacap cohort. Monday’s tape — Nvidia up, AMD flat, Apple down — is an early, imperfect illustration of that rotation risk.

A 6.4-point spread from Microsoft’s top to Apple’s bottom is the signature of rotation, not a rising tide.

Apple as the outlier

Apple was the only name in red, down 1.54% to $304.15. On a day when Microsoft and Nvidia found buyers, Apple’s underperformance stands out. We won’t over-read a single session, but the relative weakness is worth watching if the market continues to reward chip exposure over the broader consumer-tech and platform names. Nothing in the data explains the move, so treat it as a data point, not a diagnosis.

The macro backdrop

Beyond equities, the macro headlines carried a currency angle. The U.S. Treasury and Federal Reserve reportedly joined Japanese counterparts in a historic joint intervention to boost the yen, confirmed by Japan’s Ministry of Finance. Elsewhere, deal chatter moved pharma names, with reported merger talks between AstraZeneca and Bristol Myers Squibb — a tie-up analysts described as ‘odd.’ Neither directly explains Monday’s tech dispersion, but both underscore a market where policy interventions and M&A speculation are shaping cross-asset sentiment.

Bottom line

The session rewarded selectivity. Microsoft (+4.86%) and Nvidia (+2.78%) did the heavy lifting; AMD (+0.35%) treaded water; Apple (-1.54%) lagged. With JPMorgan flagging a preference for semiconductors over hyperscalers and a friendlier view on non-U.S. equities into later 2026, the leadership debate inside big tech is very much alive. Watch whether the chip bid broadens beyond Nvidia — or whether the rotation stays as narrow as it looked on Monday. This is informational only, not investment advice.

Disclaimer: Content is informational only and is not investment advice.